The U.K. government and pharma have reportedly reached a deal to improve market access and broaden efforts to encourage innovation, STAT reports.
According to the report, the agreement would deploy spending caps on brand drugs, as well as measures to speed up cost-effectiveness assessments.
The deal calls for the National Health Service to expedite approvals for new medications involving five unidentified therapeutic categories. Drugmakers, per the report, have said they’ll implement an annual two percent cap on sales growth of brand drugs.
Click here to read the full report on STAT. (Paid subscription required)